|
|
|
|
|
|
2007
20 February 2007, Cambridge, (Cambridge, UK) the leading contract research organisation and biological resource supplier today announced that it has been awarded a large genotyping project by The Institute of Human Genetics at Newcastle University on behalf of two National Consortia, for a study into vesicoureteric reflux, a congenital condition which can lead to renal failure. The MRC funded project, to genotype more than 1400 human samples from affected families in the UK and Slovenia was recently subject to an EU tender and Geneservice (GSL) was selected on a range of criteria including: technical specification, price, quality and delivery terms. Financial details of the award were not disclosed. GSL will initially amplify and quality check the DNA samples using Whole Genome Amplification. Samples will be analysed using high-density Affymetrix GeneChip® Human Mapping arrays to produce genotypes that will then used to perform a whole-genome linkage and association study. The project will begin immediately. The number of samples genotyped in any genome scan is one of the most important factors in determining power. The reduced cost of the Affymetrix high-density arrays coupled with GSL's ISO 9001:2000 certified processes enables more samples to be run, thereby increasing the power of genetic association studies. Nick Leaves, Operations Director at GSL said ' We're delighted to have been selected as the best Service Provider for this project. The Affymetrix - GSL partnership on this project will deliver an experimental investigation that could only have been dreamed of just a few years ago. In addition, the cost per genotype is very low because of recent price reductions by Affymetrix. This simply means the customer gets more great data for less money.' Contact:Nick Leaves Operations Director Geneservice 2 Cambridge Science Park Milton Road Cambridge CB4 0FE Telephone: +44(0)1223 432600 Fax: +44(0)1223 432601 E-mail: contact About Geneservice Geneservice is a worldwide leader in the provision of genomic contract research and the distribution of biological resources for life science research. Since the company's conception, the genomic services and products have been used throughout the academic, industrial, and government research sectors in fields spanning molecular biology, genomics, proteomics, drug discovery and toxicology. Geneservice headquarters are based in Cambridge, UK, visit www.geneservice.co.uk for more information. NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.
2006November 2006
29 November 2006: Geneservice (Cambridge, UK) the leading contract research organisation and biological resource supplier today announced the completion of a worldwide license agreement to distribute selected biological resources developed by world renowned Roswell Park Cancer Institute (RPCI). This new license agreement reinforces Geneservice's position as the leading provider of biological and genomic resources to life science researchers worldwide. Geneservice is one of the largest cDNA and genomic clone distribution companies in the world, and its portfolio of over 12 million clones is constantly growing through license agreements with leading academic institutions. The Roswell Park Cancer Institute is a cancer research and treatment center located in Buffalo, New York. Founded in 1898 by Dr. Roswell Park, it was the first dedicated medical facility for cancer treatment and research in the United States. The facility is involved in drug development and conducts clinical research for cancer treatment. Commenting on the importance of the agreement, Tom Weaver, CEO stated, 'This agreement increases open access to the international scientific community to one of the most useful genomic resources ever created. Some of the libraries now available include those used to sequence the human and mouse genomes. These are extremely useful for analyzing and engineering long stretches of DNA for studies in gene regulation, disease mapping and diagnositcs, imprinting, and chromosome dynamics. Such libraries are an important addition to our current product portfolio which also includes important cDNA and RNAi collections" The Mouse Bac library is available now, for futher information please click here. The Human BAC tilepath library will be available early 2007, therefore please register your interest as soon as possible via the website or by email to info@geneservice.co.uk. Contact:Tom Weaver or Andy Walker Geneservice 2 Cambridge Science Park Milton Road Cambridge CB4 0FE Telephone: +44(0)1223 432600 Fax: +44(0)1223 432601 E-mail: info@geneservice.co.uk Notes to Editors: About Geneservice Geneservice is a worldwide leader in the provision of genomic contract research and the distribution of biological resources for life science research. Since the company's conception, the genomic services and products have been used throughout the academic, industrial, and government research sectors in fields spanning molecular biology, genomics, proteomics, drug discovery and toxicology. Geneservice headquarters are based in Cambridge, UK, visit www.geneservice.co.uk for more information
London, UK; Cambridge, UK; Amsterdam, Netherlands 27 September 2006: Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, today announce that they have granted Geneservice Limited (Geneservice) a worldwide exclusive licence to distribute the pSUPER RNA interference (RNAi) vector system and pRETROSUPER vector-based short hairpin RNA (shRNA) library generated by researchers at the Netherlands Cancer Institute (NKI). The pSUPER RNAi vector system, developed by Dr Reuven Agami at the Netherlands Cancer Institute (NKI), enables stable and prolonged inhibition of target gene expression in mammalian cells. The pRETROSUPER vector-based library, consisting of almost 24,000 shRNAs complementary to approximately 8000 genes, was developed by Drs Rene Bernards and Roderick Beijersbergen and their team, also based at the NKI. With an emphasis on oncology-related genes, the library includes a high proportion of candidate drug targets. The library, contains three target sequences per gene, is sequence validated and is available in single well format, thereby facilitating high-throughput target validation in mammalian cells. The pRETROSUPER platform allows introduction of shRNA expression vectors by transfection and retroviral infection. Contacts:Dr Roisin NicAmhlaoibh Business Manager Cancer Research Technology Limited +44 207 269 3640 To register your interest in receiving this resource please contact: Dr Sebastien Allious Head of Genomic Reagents Geneservice +44 1223 432609 Notes to Editors: About Geneservice Geneservice was launched in August 2005 following a successful management buyout of the UK Medical Research Council Biological Resource Centre (MRC Geneservice). Geneservice offers access to high quality genomic products and leading contract research for applications in the lifesciences, clinical research and development. Visit the Geneservice website at www.geneservice.co.uk for more information. About The Netherlands Cancer Institute The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL) combines a scientific research laboratory with a specialised clinic. It is the only dedicated cancer center in the Netherlands. The primary objective of the NKI-AVL is to make a substantial contribution to combating cancer through a unique interaction of scientific research and clinical application. For more information, please visit www.nki.nl About Cancer Research Technology Cancer Research Technology Limited (CRT) is an oncology-focused development and commercialisation company that realises cancer patient benefit from publicly- funded research worldwide. CRT works closely with leading international cancer scientists, their institutes and funding bodies to protect, develop and commercialise oncology-related discoveries. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. Further information about CRT can be found at www.cancertechnology.com August 2006
1 August 2006: Geneservice (Cambridge, UK) the leading contract research organisation and biological resource supplier today announced the completion of a world wide agreement to distribute selected genomic resources developed by world renowned Wellcome Trust Sanger Institute. This agreement further strengthens Geneservice's position as the leading genomic resource supplier. These Sanger Institute genomic resources are a significant addition to the reagent portfolio, and will initially add three important libraries to the existing portfolio of over 12 million clones. All genomic resources will be available to order on-line, via the Geneservice website at http://www.geneservice.co.uk/products/sanger, customers will receive shipments quickly and efficiently. All orders will be backed by the usual exceptional level of customer service and technical support, that customers have come to expect from Geneservice. Commenting on the importance of the agreement, Tom Weaver, CEO stated, "Geneservice is extremely pleased to be working with Genome Research to market these unique resources, developed at The Sanger Institute. Geneservice originated from the UK Medical Research Council when it was part of Human Genome Program on the Hinxton Genome Campus, so it is exciting to continue working closely with the Sanger. It is our aim to provide a portal for scientists from around the world access to one of the most advanced research programs in the field of genomics. This agreement further re-enforces our commitment to enabling rapid and open access to the highest quality biological tools for life science research." Contact:Tom Weaver or Andy Walker Geneservice 2 Cambridge Science Park Milton Road Cambridge CB4 0FE Telephone: +44(0)1223 432600 Fax: +44(0)1223 432601 E-mail: contact About Geneservice Geneservice was launched in August 2005 following a successful management buyout of the UK Medical Research Council Biological Resource Centre (MRC Geneservice). Geneservice offers access to high quality genomic products and leading contract research for applications in the lifesciences, clinical research and development. June 2006
2 June, 2006: Geneservice (Cambridge, UK) the leading contract research provider today announced they have been selected as one of three preferred sequencing service providers for the 35 Medical Research Council (MRC) research sites across the UK. Geneservice is a privately owned company employing around 30 people with considerable experience in providing genomic contract research services to a wide range of customers both in the UK and abroad. Geneservice is ISO 9001:2000 accredited and offers speedy, high quality data to its sequencing customers The company has a dedicated and highly skilled DNA sequencing team who will provide an efficient and proven service to the MRC scientists. Roger Turner, Finance and Commercial Director was pleased that Geneservice had been selected and commented "Geneservice has been providing several of the MRC sites with high quality DNA sequencing services for some years, and we are pleased to have been selected as one of the preferred supplies for the three year contract. We are committed to providing exceptional customer support and the very best sequencing data possible using the latest technology" Contact:Roger Turner or Karen Chandler-Smith Geneservice 2 Cambridge Science Park Milton Road Cambridge CB4 0FE Telephone: +44(0)1223 432600 Fax: +44(0)1223 432601 E-mail: contact About Geneservice Geneservice was launched in August 2005 following a successful management buyout of the UK Medical Research Council Biological Resource Centre (MRC Geneservice). Geneservice offers access to high quality genomic products and leading contract research for applications in the lifesciences, clinical research and development. May 2006
30 May, 2006: Geneservice (GSL) of Cambridge England, and Kabushiki Kaisha DNAFORM, of Tokyo Japan, today announced exclusive distribution agreements whereby GSL and DNAFORM will jointly distribute FANTOM™ clones developed by RIKEN as well as other unique genomic resources created by leading international research institutions like the NIH. This strategic alliance will give the international life science community access to the world's largest collection of cDNA and genomic clone resources from key model organisms such as human, mouse, rat, primate, C. elegans, Drosophila, and Xenopus. "We are excited at the prospect of Geneservice partnering with KK DNAFORM for the ability to combine our clone collections with the impressive resources from RIKEN, and expanding our territorial reach into Asia" said Tom Weaver, CEO for Geneservice. KK DNAFORM, which is actively working on exploiting the RIKEN cDNA library technology, for which it holds exclusive patents, also welcomed this partnership. "We see this strategic alliance as a way to rapidly increase our product portfolio offered in Japan and other Asian countries, and to effectively market our RIKEN FANTOM™ Clones particularly in the EU" stressed Hirohumi Ujita, KK DNAFORM's CEO. The new alliance was also welcomed by members of the research community, and recognized as a great step forward to increase the awareness about these clone collections in the public domain, and to make them more easily accessible for researches. Professor Yoshihide Hayashizaki, Project Director of the Genome Exploration Research Group at RIKEN, commented "This partnership is really very important to us, and we are hoping that it will give more researches access to our FANTOM™ Clones. Moreover, it is good to know that for the first time a clone provider in Japan will offer all the clones from the international genome projects." Marc Vidal from the DFCI added "The new paradigm of genomics and systems biology requires the creation of genome-wide clone resources. It is essential that international efforts like this take place to make such valuable resources available to the research community, in particular in Asia where a dedicated clone provider was missing." Contact for more information: Dr Andrew Walker, Resource Development Manager, +44 (0)1223 432600, ajwalker@geneservice.co.uk Notes to editors About Geneservice: GSL is an innovative genomics-based products and contract research company recently formed from the UK Medical Research Council. Their mission is to provide an archiving and distribution portal for emerging genomic reagents, such as bacterial clones and Human DNA samples, generated by academic groups and consortia internationally. GSL also provides access to state-of-the-art high throughput technologies to academic and commercial clients for the study of gene expression and gene mapping, including disease gene identification, DNA sequencing, extraction and whole genome amplification; micro satellite and SNP genotyping; and RNA expression profiling. Geneservice's one-stop service program for genomics researchers is highly regarded for its quality and customer service. For more information please visit www.geneservice.co.uk About DNAFORM. DNAFORM was established as a RIKEN Venture to commercialise technologies for the analysis of complex transcriptomes developed as part of the RIKEN Mouse Encyclopaedia Project. DNAFORM's technology platform is based on the patented RIKEN Full-Length cDNA Cloning Approach, which offers effective means for Transcriptome Analysis along with resources for target gene cloning. Expanding on this platform, novel approaches can be offered for Transcriptome Annotation based on 5'-Tag sequencing (CAGE), and the identification of genes regulated on the level of Alternative Splicing (ASSETS). In combination with our flexible Library Construction Program, the DNAFORM technology platform can support research and development in Proteomics, Gene Regulation, Gene Discovery, RNAi, or SNP Analysis. For the promotion of science and the easier availability of DNA clones to the research community, DNAFORM developed further together with RIKEN the concept of the DNABook™, which brings together clones of interest and the related information in a printed format easy to handle, store and use. For more information please visit www.dnaform.jp May 2006
15 May, 2006: Geneservice Limited (GSL) Cambridge, UK, the leading contract research organisation and biological resource centre and RNAx GmbH (RNAx), Berlin, Germany, a company specialized in RNAi validation technology, announced today the launch of their new mRNA expression PhenoFiler™ service platform. This new platform brings together both companies unique expertise to create a single platform for gene discovery and validation. Under the terms of the agreement RNAx provides GSL and its customers with in vitro si- and shRNA validation technology to complement GSL's gene expression profiling and network analysis service, and vice versa. PhenoFiler™ will provide researchers with a complete solution for comprehensively profiling tens of thousands of genes and then immediately screening for molecular or cellular phenotypes in a co-ordinated set of experiments. RNAx has developed a robust automated platform for the customized, rapid and cost effective validation of siRNAs, shRNAs and genetic targets in a broad variety of commonly used cell lines and primary cells, making the screening, selection and functional validation of si- and shRNAs affordable, even at high numbers of targets. Through a number of partnerships with leading European biotech companies, RNAx makes RNAi technology available to many applications during the target discovery and validation process - all the way from gene expression analysis to in vivo validation of more advanced targets. GSL, a contract research organisation and biological resource centre, recently formed from the UK Medical Research Council that brings with it more than 10 years experience as a national core service laboratory and was one of the first national service providers of mRNA expression analysis in Europe. GSL has also developed novel bioinformatics tools for identifying important relationships between genes, establishing networks based on expression data. "This agreement gives benefits to both companies: GSL's customers through our one-stop approach will have access to gene silencing technology, and RNAx' customers can take advantage of the full range of GSL's technologies. The customer will not have the need to look for additional providers, and will deal with our two companies as if it was one entity. This will simplify and speed up the service for the customer. Results will be available faster, because our two companies know exactly how to integrate our technologies, commented Joerg Poetzsch, CEO of RNAx. "We are very pleased to partner with RNAx, as this adds an important new dimension to our contract research capabilities and customer value", said Tom Weaver, CEO of Geneservice. About Geneservice About RNAx GmbH 05 May 2006 Geneservice are happy to announce the distribution of our forth C. elegans resource in as many months! With over 10 thousand knockdown targets, some of which are unique to this library, the ORF-RNAi library is an ideal resource for large scale-screening and individual knockdown experiments. For more information, please consult the ORF-RNAi website. 20 April 2006
Geneservice (Cambridge, UK) today announced it has received the International Standards Organisation’s (ISO) 9001:2000 certification for the provision of functional genomic products and contract research to academic and commercial research communities worldwide. This follows external validation by Lloyds Register of Quality Assurance (LRQA) a UKAS accredited quality certification body. ISO 9001 is an internationally accepted standard that represents good management practices and aims to ensure that organisations consistently deliver the products or services that meet their clients’ quality requirements. The achievement of ISO9001:2000 approval reinforces Geneservice’s continued commitment to identify and meet the needs and expectations of its customers and achieve, maintain and improve overall operational performance and capabilities. Tom Weaver, CEO of Geneservice commented Contact:
About Geneservice
March 2006
Cambridge, UK Geneservice, is pleased to announce that the Wellcome Trust Sanger Institute has chosen Geneservice to provide whole genome amplification for circa 25,000 samples from multiple studies including the Wellcome Trust Case Control Consortium (WTCCC), EPIC (obesity), MalariaGen, and the International 1q type 2 diabetes consortium. Large sample collections are essential in investigating the molecular basis of common genetic diseases and susceptibility to pathogens. Expanding the amount of DNA available will allow multiple future experiments on these precious samples that have been collected over many years. Evaluation of suppliers, was based on a common set of samples tested post-amplification with the Affymetrix Genechip as well as Illumina Golden Gate and Infinium technologies. The selection of Geneservice was based on a combination of responsiveness, performance, quality of service and value for money. Tom Weaver, CEO of Geneservice commented Panos Deloukas of the Wellcome Trust Sanger Institute added Contact:
About Geneservice
About Whole Genome Amplification
About Wellcome Trust Sanger Institute
27 February 2006
Cambridge, UK Geneservice, today announced a five-year strategic alliance with VWR for sales representation of the company's leading contract research platforms. Customers in Europe, USA and the UK will now be able to access industry leading genotyping, gene expression and DNA handling capabilities at Geneservice via their local VWR specialist service representative. VWR's sales and marketing operation currently serves over 250,000 customers with an extensive worldwide specialist sales network. This strategically important agreement, the first since the management buyout of MRC Geneservice in 2005, is further evidence of Geneservice's commitment to providing the very latest discovery contract research platforms to a growing customer base. Tom Weaver, CEO at Geneservice commented The alliance offers an excellent balance and fit between Geneservice's established expertise in genomic contract research and VWR's marketing capabilities, global market strength and representation. Geneservice customers will benefit from the proximity with their local VWR specialist service representative, and will have direct access to leading technology and a team of dedicated, highly qualified scientists with extensive project management experience at Geneservice. With over 10 years experience as a national genomics core laboratory and bioinformatics infrastructure, Geneservice has both the capacity and ambition to move beyond the UK market. Working with VWR will substantially increase Geneservice's exposure by promoting its expert contract research program and customer service to academic, clinical, government, biotech and pharma labs world-wide. Dr. Weaver also highlighted that VWR International is a global distributor providing a diversified range of products and has recently established VWR Biosciences to provide specialist services, such as those provided by Geneservice, to the bioscience and lifescience Industries. VWR's primary customers work in the pharmaceutical, life science, chemical, technology, food processing and consumer product industry throughout North America and Europe. Zishan Haroon, General Manager and Global VP of VWR BioSciences commented Contact: Tom Weaver, CEO or Roger Turner, Finance and Commercial Director Geneservice 2 Cambridge Science Park Milton Road Cambridge CB4 0FE Telephone: +44(0)1223 432600 Fax: +44(0)1223 432601 Email: info@geneservice.co.uk
About Geneservice
February 2006 After the success of the Mouse DNABook™, Geneservice are happy to announce the distribution of the more than 100 thousand FANTOM™ 3 clones. The clones are full-length sequenced, with comprehensive supporting annotation and databases. Single clones or the complete library are ready for distribution! For more information, please go to our FANTOM™ 3 webpage. February 2006 Geneservice Announce the Appointment of Dr Andy Richards as Non-Executive Chairman. Geneservice (Cambridge, UK), announced today that the Board of Directors has appointed Dr Andy Richards as non-executive Chairman. Dr Richards is a well known Biotechnology entrepreneur having been a founder of several successful Cambridge biotechnology companies including Chiroscience, Arakis, Cambridge Biotechnology and Daniolabs. He holds a number of non-executive director positions including Vectura group plc, Daniolabs, Biowisdom, Babraham Bioscience Technology and Cancer Research Technology (the commercial arm of CR-UK). He is a director of the UK Bioindustry Association and this year was voted both Cambridge Evening News Businessman of the Year as well as one of the Top100 Living Contributors to Biotechnology. This new appointment follows on from the successful management buyout of Geneservice from the UK MRC in August 2005. On his appointment to the board of Geneservice Dr Richards said, "Geneservice have already demonstrated that they have real potential to develop into a major provider of specialist high quality contract research and reagents to the life sciences and rapidly growing biotechnology industry. The strong and committed team that led the management buyout have ambitious plans to grow Geneservice and I am delighted to have the opportunity to help them achieve this." CEO of Geneservice Dr Tom Weaver added, "We are a young company and our aim was to bring in someone with extensive knowledge of biotechnology and experience with small startup companies. Andy's expertise and networking ability is exactly what we need at this stage of our development, plus he shares our vision to rapidly build up our product and service portfolio. His infectious passion for innovation and getting the most out of our people, operations and business opportunities will add so much to our senior management team." Notes to editors Geneservice Limited was launched in August 2005 following a successful management buyout of the UK Medical Research Council Biological Resource Centre (MRC geneservice). GSL offers genomic products and expert contract research for applications in the life sciences and clinical research and development. It provides access to high quality, leading edge genomic products essential for manipulating gene and protein function in the majority of model organisms, including Mouse and Man. GSL also carries out expert technology support on a contract basis. The management team comes with a proven track record at running a National Biological Resource Centre and a super-core laboratory, guaranteeing excellent customer service and access to a "one-stop-shop" for many genomic applications. Our market has international reach with over 900 institutional customers from a database of 21,000 registered users from over 40 countries, and includes: Universities, Charities, Government labs, Biotech and Pharmaceutical companies. These attributes place GSL in a powerful and unique position to fully utilize the commercial potential of emerging genomic research in academia and translate these discoveries into validated, high quality, products and contract research. For more information about Geneservice Limited, its products and research support program log on to the website at www.geneservice.co.uk. February 2006 Geneservice and the University of Cambridge Department of Genetics are pleased to announce that from the 1st February 2006 the will be some exciting changes to the availability of contract sequencing within the city. The two sequencing teams are joining forces to give customers an improved sequencing and genotyping service at a lower price. 2005December 2005 A set comprising of more than six thousand C. elegans promoters have been launched! The library format is in 71-microtitre plates, 96-well format. Single clones, full-set or re-arrayed subsets are available from us. For further information, please go to C. elegans Promoterome Library November 2005 We are happy to announce the launch a comprehensive C. elegans Fosmid library. The N2 based library is the first of it's kind to be distributed, and will be and excellent accompaniment to our every increasing portfolio of resources. "C. elegans re-arrays" Owing to the great success of Julie Ahringer's C. elegans RNAi feeding library, Geneservice are launching 3 subsets of the library. The sub-sets knockdown genes associated with Chromatin, Phosphatase and Transcription factors.
September 2005 Whole Genome Amplified (WGA) DNA aliquots have been prepared from a diverse range of organisms, to the highest of qualities. Downstream applications may include: PCR, library construction, southern blotting and SNP analysis. If you would like further information please visit our WGA aliquot information page.
September 2005 Launch of Mouse Genome Encyclopaedia In AD 105, the Chinese court official, Ts´ai Lun, invented papermaking. Since then, this ubiquitous material has continued to play an influential role in many of our civilizations. As we embark into the new Millennium however, we are dominated by the progress that has been made in computer science, thus triggering a complete change in our commercial and private communication behaviour. Does this mean that the paper era will come to an end? The answer is most definitely "No". This new resource is one of the many reasons why. Geneservice is happy to announce the distribution of the Mouse Encyclopaedia DNABook™. The book comprises of 60,770 full-length mouse cDNA clones spotted onto paper and bound in an A5 size book. The book is supported by databases for searching individual clones by either location in the book, or gene ID. Furthermore, many functional annotations may also be accessed. For more information please visit: Mouse Genome Encyclopaedia.
6th June 2005 January 05 2004June 2004 Cambridge, UK - Genome researchers struggling with minute quantities of DNA and degraded samples can breathe a sigh of relief with the launch of MRC geneservice's (MRCg) Whole Genome Amplification service. The new service bolsters MRCg's range of genomic services that include DNA sequencing, SNP genotyping, microsatellites and RNA expression analysis. With the addition of Whole Genome Amplification (WGA), MRCg will be able to amplify small quantities of precious DNA to provide sufficient quantities for larger scale and multiple projects. MRCg's one-stop service for genomic researchers is setting the standards for quality, turnaround time and price, and WGA customers will also benefit from discounts on subsequent genotyping. In order to offer the best possible service to genotyping and sample banking clients, MRCg undertook its own comparison of different WGA methods. The result has been an agreement with Molecular Staging Inc (MSI) for MRCg to provide a Whole Genome Amplification service using MSI's proprietary REPLI-g™ technology. 'Technically the MSI system proved superior on our samples to the other systems tested and provides a very effective QC for the end product. This prevents the researcher wasting valuable time and money on genotyping highly degraded samples' said Dr Cheng-Eng Ang, MRC DNA Bank Network Manager, who will be managing the service. 'Partially degraded samples and irreplaceable small quantities
of DNA are two of the most common causes of failure in genotyping
projects' said Roger Turner, MRCg's CBO. 'Whilst no method
can guarantee to rescue highly degraded DNA, MSI's system
provides assurance on quality before embarking on further
work and provides sufficient quantities for multiple future
experiments.' 'The whole genome amplification technology is truly cutting
edge and will have a substantial impact on many applications,
such as genetic mapping, pathogen identification, forensics
and embryonic disease diagnosis. That is why a key milestone
for our DNA banking program has been the introduction of effective
whole genome amplification for the long term archiving of
clinical samples and genotyping. By partnering with MSI we
are able to meet our in-house R&D objective and also provide
a beneficial contract service open to the research community.'
said Tom Weaver, MRC geneservice's CEO.
Molecular Staging Inc. January 2004 SILENCE OF THE GENES MRC geneservice launches comprehensive Drosophila RNAi library. Cambridge, UK - MRC geneservice has announced the launch of their extensive new Drosophila RNA interference (RNAi) library. Encompassing over 90% of the Drosophila genome, researchers can study the function of specific genes through genome-wide screens - a first step in shedding new light on disease processes and possible drug targets. To read full press release please click
here (Adobe PDF format 244K). Available January 2004 Drosophila genome RNAi library This resource is arrayed in 142 96-well microtitre plates
and can be ordered as individual plates or as entire set for
genome-wide screen. We are also able to offer dsRNA synthesis
service for the plates of your choice. Please send your requests
to info@geneservice.co.uk
for more details.
2003Available NOW - 24th November 2003 The Mouse Pancreas Genes subset [IRBD, IRBE] G PROTEIN COUPLED RECEPTORS (GPCR) Clone set [IRBI.IRBF] For more details please click
here. 20th November 2003 Dear Researcher MRC geneservice announces new benefits
for its Affymetrix clients MRCg is pleased to announce that it is the first UK service provider to own the GeneChip Scanner 3000 enabled for High Resolution Scanning. This allows us to make our Affymetrix GeneChip service available to you on Affymetrix latest high-density chips ONLY READABLE WITH THE NEW SCANNER. We are therefore able to make significantly more data available to you at our lowest ever prices. Our price scales have been lowered and simplified, with price breaks for larger experiments. All prices can be seen here. here. For orders placed and samples received by 31 January 2004 we will offer a further 10% DISCOUNT on these prices. We will also agree with you a GUARANTEED DELIVERY DATE for your results. If you deliver samples by the agreed time and we fail to deliver your results by the agreed date you will receive a further 10% DISCOUNT! Examples of the NEW services we are able to offer are:
Data sheets on the above products can be found at http://www.affymetrix.com/products/arrays/index.affx To discuss your requirements further and place your order please contact us by e-mail microarrays@geneservice.co.uk quoting reference AFFY03. We look forward to hearing from you. Yours Sincerely Roger J L
Turner BSc FCA |
|
© Source BioScience plc 2008 Contact webmaster |
| Quality | | Terms and Conditions | |
